236K shares changed hands on Tuesday. Shares saw a steep decrease in trading volume of 87.34% under the normal average daily volume.
Investors are a little more bearish on the company if you put credence in the change in short interest. The firm realized a rise in short interest of 0.43% as of the latest report on October 13, 2017. Short interest increased from 895,054 to 898,939 over that period. Days to cover decreased from 5.0 to 5.0 and the percentage of shorted shares is 0.03% as of October 13.
These firms have modified their investment in QURE. Ubs Group Ag downsized its ownership by selling 5,126 shares a decrease of 94.9%. Ubs Group Ag owns 274 shares worth $2,000. The total value of its holdings decreased 93.5%. Cutler Group LP trimmed its stake by shedding 608 shares a decrease of 75.2% as of 09/30/2017. Cutler Group LP controls 200 shares with a value of $1,000. The value of the position overall is down by 80.0%.
As of the end of the quarter P.a.w. Capital Corp had disposed of a total of 20,000 shares trimming its stake by 16.0%. The value of the investment in (QURE) went from $774,000 to $1,008,000 increasing 30.2% quarter over quarter. As of quarter end Advisor Group, Inc. had bought 920 shares growing its holdings by 13.9%. The value of the total investment in Uniqure N.V increased from $41,000 to $72,000 a change of $31,000 for the reporting period.
On November 7, 2017 Evercore ISI released research on QURE by announcing an initial rating of “Outperform”. Equity analyst Leerink Swann raised the price target of the stock on November 7 boosting the projection from $19.00 to $26.00 and stated a “” rating.
Leerink Swann raised the price target on October 20 changing the price objective from $17.00 to $19.00 and issued a “Outperform” recommendation.
The company is now down by 4.95% percent from yesterday’s close. Uniqure N.V currently has a P/E ratio of N/A and the market value is 455.23M. As of the latest earnings report the EPS was $-2.61 with 30.80M shares now outstanding.
uniQure N.V. (uniQure) is a gene therapy company. The Company is involved in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships. The Company?s product candidates include AMT-060 for Hemophilia B, AMT-130 for Huntington’s disease, S100A1 for congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). uniQure has established clinical proof-of-concept in its lead indication, hemophilia B and has achieved pre-clinical, proof-of-concept in Huntington’s disease. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure..